Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
296
datasets available to search
ShareScore release 0.9.0
Dataset results
296 results for “TP53”
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation
ClinicalTrials.gov study NCT02688907. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT07008638. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53
ClinicalTrials.gov study NCT04966923. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer
ClinicalTrials.gov study NCT06107868. IPD Sharing: NO. Countries: 1. Publications: 0.
Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
ClinicalTrials.gov study NCT06062641. IPD Sharing: NO. Countries: 1. Publications: 0.
Advanced Refractory Solid Tumors With TP53 Mutations Register Study
ClinicalTrials.gov study NCT03927599. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation
ClinicalTrials.gov study NCT06908434. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multice
ClinicalTrials.gov study NCT07240194. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.
ClinicalTrials.gov study NCT05785208. IPD Sharing: NO. Countries: 1. Publications: 0.
Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type
ClinicalTrials.gov study NCT03714958. IPD Sharing: NO. Countries: 1. Publications: 0.
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
ClinicalTrials.gov study NCT06690281. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
ClinicalTrials.gov study NCT05622058. IPD Sharing: Not stated. Countries: 4. Publications: 0.
Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia
ClinicalTrials.gov study NCT02827617. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
ClinicalTrials.gov study NCT05396859. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
ClinicalTrials.gov study NCT07198074. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
ClinicalTrials.gov study NCT07060989. IPD Sharing: NO. Countries: 2. Publications: 0.
A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.
ClinicalTrials.gov study NCT07017816. IPD Sharing: NO. Countries: 1. Publications: 0.
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy
ClinicalTrials.gov study NCT02448329. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
ClinicalTrials.gov study NCT06136351. IPD Sharing: NO. Countries: 1. Publications: 0.
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
ClinicalTrials.gov study NCT06517511. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.